Skip to content


  • Research article
  • Open Access
  • Open Peer Review

β2-Adrenergic receptor promoter haplotype influences the severity of acute viral respiratory tract infection during infancy: a prospective cohort study

  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 1,
  • 4,
  • 5,
  • 1 and
  • 6Email author
BMC Medical Genetics201516:82

  • Received: 9 January 2015
  • Accepted: 9 September 2015
  • Published:
Open Peer Review reports



Despite the significant interest in β2-Adrenergic receptor (ADRB2) polymorphisms related to asthma, whether ADRB2 genetic variants are similarly associated with acute respiratory tract infections have not been studied. We hypothesized that genetic variants in ADRB2 associated with a response to asthma therapy during an asthma exacerbation were also associated with severity of acute respiratory tract infections.


To test this hypothesis, we genotyped 5 common polymorphisms in the promoter region and coding block of the ADRB2 gene (loci -2387, -2274, -1343, +46, and +79) from 374 Caucasian and African American term infants who were enrolled at the time of acute respiratory illness over four respiratory viral seasons. Severity of respiratory tract infections was measured using a bronchiolitis severity score (BSS; range = 0-12, clinically significant difference = 0.5) with a higher score indicating more severe disease. We assigned the promoter, coding and combined promoter and coding haplotypes to the unphased genotype data. The associations between each of these five single-nucleotide polymorphisms (SNPs) as well as the haplotypes and infant BSS were analyzed using nonparametric univariate analysis and multivariable proportional odds model separately in Caucasians and African Americans.


There was no significant association between infant BSS and each of the SNPs in both Caucasians and African Americans. However, promoter haplotype CCA was associated with a decreased BSS in African Americans in a dose dependent manner. The median (interquartile range) BSS of infants with no copies of the CCA haplotype, one copy, and two copies of the CCA haplotype were 5.5 (2.0, 8.0), 4.0 (1.0, 7.5), and 3.0 (1.0, 4.0), respectively. This dose dependent relationship persisted after adjusting for infant age, gender, daycare exposure, secondhand smoke exposure, prior history of breastfeeding, siblings at home, and enrollment season (adjusted odds ratio: 0.59, 95 % confidence interval: 0.36, 0.98). There was no similar protective relationship of haplotype CCA on severity of respiratory tract infections identified in Caucasians.


ADRB2 genotype may be predictive of severity of acute respiratory tract infections in African Americans, and potentially identify a subset of infants who may respond to beta-agonist therapy.


  • Respiratory Syncytial Virus
  • Lower Respiratory Tract Infection
  • Acute Respiratory Infection
  • Respiratory Viral Infection
  • Human Airway Smooth Muscle


Respiratory tract infection is common in infants and young children and is a major public health problem in this age group [1]. It is mainly caused by infection of seasonal viruses, such as respiratory syncytial virus (RSV) and rhinovirus [24]. Most infections manifest as an upper respiratory infection, while 20–40 % develop lower respiratory infection, and a small number (2 – 3 %) of infected infants require hospitalization [5, 6]. This is of particular concern as infants with lower respiratory viral infection are at increased risk of developing recurrent wheezing or childhood asthma [713]. Several risk factors have been identified for the development of severe lower respiratory viral infections, such as premature birth, young age, being born in relation to the RSV season, underlying chronic lung disease, congenital heart disease, high parity, young maternal age and poor socioeconomic factors [1416]. Recently, genetic polymorphisms have been identified which are associated with severe viral infection [17, 18]. Many of the identified genetic variants associated with severe lower respiratory tract infections are also associated with and pathways common to asthma, including innate immune genes involved in cytokine and chemokine signaling, and epithelial cell function [13, 17, 1923].

As the clinical hallmark of asthma is wheezing, and therapy includes beta agonists, a number of clinical studies over the past 2 decades have examined the relationship between genetic variants in β2-Adrenergic receptor (ADRB2) and asthma [2430]. The polymorphism that resulted in the Gly16 allele was associated with decreased bronchodilator responses in early clinical studies; however, larger clinical studies have provided equivocal results [3133]. Other genetic variants in the promoter region of ADRB2 have also been associated with asthma severity [28, 34]. Despite the significant interest in ADRB2 polymorphisms related to asthma, the relative contribution of ADRB2 genetic variants to severity of respiratory viral infections has not been established. As wheezing is also the clinical hallmark of lower respiratory viral infections, and variable response to bronchodilators has been demonstrated in infants hospitalized with RSV lower respiratory viral infections, it is possible that ADRB2 genetic variants also contribute to the severity of acute respiratory viral infections [35, 36].

The aim of the present study was to explore associations between the genetic variants in ADRB2 that have been associated with a response to asthma therapy during an acute asthma exacerbation and the severity of infant acute respiratory viral infections. We examined the relationship between 5 common polymorphisms in the promoter region and coding block of the ADRB2 gene and infant severity of respiratory infections in a prospective cohort of Caucasian and African American infants.


Study population

In order to examine the association of genetic variants in the regulatory regions of the ADRB2 gene and the severity of viral respiratory infections during infancy, we conducted an analysis of infants enrolled in the Tennessee Children’s Respiratory Initiative (TCRI), a prospective cohort of mother-infant dyads enrolled during an infant’s acute viral respiratory illness over four respiratory viral seasons, 2004–2008. Term (≥37 weeks) and non-low birth weight (≥2275 g) infants who were otherwise healthy with no significant co-morbidities or cardio-pulmonary disease were eligible, with oversampling for hospitalization infants. Eighty five percent of enrolled subjects had at least one respiratory virus identified by polymerase chain reaction (RSV, rhinovirus, influenza, parainfluenza, Human Metapneumovirus, and coronavirus); 56 % had lab-confirmed RSV infection. The rationale, methods, and detailed inclusion and exclusion criteria have been reported previously [37]. Although 630 infants were enrolled in TCRI, this study was limited to the 261 Caucasian and 113 African American infants for whom DNA was available. The protocol was approved by the Institutional Review Board of Vanderbilt University, and mothers provided informed consent for their infants. All parents provided written informed consent for both their and their child’s study participation.

Infant acute respiratory infection severity

Infants included in this study had either upper respiratory tract infections or lower respiratory tract infections. The severity of acute respiratory infection was determined by experienced research nurses through medical record chart review using an ordinal bronchiolitis severity score (BSS). The score is an aggregate of assigned values ranging of 0–3 in categories of respiratory rate, room air oxygen saturation, the presence and extent of wheezing, and the presence and extent of flaring and retractions [3739]. The BSS ranges from 0 to 12, with higher scores indicating more severe illness and a difference of 0.5 being a clinically significant difference [40]. We measured the BSS at the end of the outpatient visit or after discharge from an inpatient admission, and the most severe recorded value was used for analysis.

Genotype determination

DNA was extracted by Vanderbilt’s DNA core laboratory from whole blood or saliva samples (Oragene by DNA Genotek) by standardized protocols. All oragene samples were processed immediately after collection, while blood samples were either processed immediately or frozen before processing. Genotyping at five pre-specified loci (-2387, -2274, -1343, +46, and +79) of ADRB2 gene was done using Taqman SM© Genotyping Assays (Applied Biosystems, Foster City, CA, USA) with predetermined primers. The five single-nucleotide polymorphisms (SNP)s were rs1432623, rs11168068, and rs2400707 at the promoter region, and rs1042713 SNP and rs1042714 SNP at the coding region of ADRB2 gene. Probes for the Applied Biosystems assays used were labeled at their 5′end with either VIC® or 6-carboxy-fluorescine (FAM) reporter dyes. The reaction components include: 2.5 μl Taqman Universal PCR Master Mix (Applied Biosystems), 0.125 μl or 0.250 μl assay mix (Applied Biosystems) and approximately 5 ng of genomic DNA in a total volume of 10 μl per single tube reaction. PCR amplification was performed in a thermal cycler (Techne TC-412) with an initial step of 95 °C for 10 min followed by 50 cycles of 92 °C for 15 s and 60 °C for 1 min. After amplification, the fluorescence of each sample was read on the ABI 7900HT (DNA Resources Core at Vanderbilt University) and analyzed with the Sequence Detection Software (Applied Biosystems). Five percent of samples were run as blind duplicates with 100 % concordance. Primers and probes for all SNPs are listed in Table 1.
Table 1

Primers and probes of the 5 ADRB2 SNPs


rs number





Forward Primer



Reverse Primer





Forward Primer




Reverse Primer




Forward Primer




Reverse Primer




Forward Primer




Reverse Primer




Forward Primer




Reverse Primer


Statistical analysis

The demographics and characteristics of the 374 infants included, with either upper respiratory infection or lower respiratory tract infection, are presented as frequencies and proportions for specific categorical variables and medians and interquartile ranges were calculated for continuous variables. All analyses were stratified by race (Caucasian or African American), as a surrogate measure of European or African ancestry, to reduce the known impact of population substructure which can produce spurious associations [41]. A pairwise linkage disequilibrium (LD) was estimated for the SNPs in ADRB2 using the standardized summary statistics D’ and r, calculated by the HaploView program (Whitehead Institute for Biomedical Research, Cambridge, MA, USA). SNPs were tested for deviations from Hardy Weinberg proportions, also using Haploview [42]. The promoter, coding and combined promoter and coding SNPs were assigned to blocks using D’ confidence interval of Gabriel et al. [43]. Individual haplotypes were estimated using the program PHASE v2.1.1 [44, 45]. The haplotype frequencies for each block were estimated using the expectation maximization (EM) algorithm, again using the HaploView program. Non-parametric Kruskal-Wallis test were applied to compare the difference in BSS among infants with each SNP genotype, as well as each haplotype genotype. Haplotype genotypes with frequency less than 2 % were excluded from haplotype analysis. We used a proportional odds model for the ordinal BSS to test the additive effect of haplotypes. Covariates included in the regression model included infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of breastfeeding, any siblings at home, and enrollment season. All analyses were conducted separately according to race. All analyses were performed using R-software version 2.11.1 ( We used a two-sided 5 % significance level for all statistical inferences.


There were in total 374 infants, 261 Caucasians and 113 African Americans, enrolled in the TCRI cohort with available DNA and at least one ADRB2 polymorphism tested (Table 2). The median infants’ age at enrollment was 11 weeks (interquartile range [IQR]: 6, 25). The average birth weight of these infants was 3317 g (standard deviation [SD]: 455.8). Among those infants, 207 (55 %) were male, 198 (53 %) were breastfed, 107 (29 %) attended daycare at the time of enrollment, 222 (60 %) were exposed to secondhand smoke, and 283 (76 %) had older siblings at home. Seventy six percent (n = 285) of infants had bronchiolitis at enrollment and 64 % (n = 239) were identified as RSV positive. The median bronchiolitis severity score was 5.5 (IQR: 2.5, 8.5). Compared to African American infants, Caucasian infants were more likely to have a higher birth weight, younger age at enrollment, been breast fed, have secondhand smoke exposure, have private insurance, have mothers who were older and had a higher education level, and have mothers who were less likely to have asthma. In addition, Caucasian infants were more to have lower respiratory tract infection instead of upper respiratory infection, and have more severe respiratory infections based on the BSS (p < 0.05).
Table 2

Characteristics of infants and their biological mothers (N = 374)


Caucasian (N = 261)

African American (N = 113)

P value

Infant characteristics

Birth weight (grams) (N = 372), median (IQR*)

3345 (3090, 3657)

3147 (2892, 3430)


Gestational age (weeks) (N = 371), median (IQR)

39 (38,40)

39 (38,40)


Male gender, n (%)

140 (54)

67 (59)


Age at enrollment (weeks), median (IQR)

10 (6, 21)

18 (7, 35)


Breastfeeding, n (%)

152 (58)

46 (41)


Daycare attendance, n (%)

68 (26)

39 (35)


Secondhand smoke exposure (N = 371), n (%)

158 (61)

64 (57)


Having siblings, n (%)

198 (76)

85 (75)


Insurance type, n (%)


111 (43)

9 (8)



135 (52)

101 (89)



15 (6)

3 (3)


Season of enrollment, n (%)

 2004 – 2005

42 (16)

21 (19)


 2005 – 2006

76 (29)

38 (34)


 2006 – 2007

75 (29)

31 (27)


 2007 – 2008

68 (26)

23 (20)


RSV positive

180 (69)

59 (52)


Lower respiratory tract infection vs. upper respiratory infection, n (%)

213 (82)

72 (64)


Bronchiolitis severity score (n = 373), median (IQR)

6.5 (3, 9)

4 (1, 7)


Maternal characteristics

Maternal age at enrollment (years)

27 (22, 31)

24 (21, 27)


Maternal education, years (n = 313), n (%)


42 (19)

16 (17)



56 (25)

41 (44)



122 (55)

36 (39)


Maternal asthma, n (%)

50 (19)

27 (24)


Abbreviations: IQR interquartile range

Table 3 lists the allele frequencies of 5 SNPs separately for Caucasian and African Americans. In both Caucasians and African Americans, infants had slightly more T, T, and G alleles for the three promoter SNP rs1432623, rs11168068, and rs2400707, respectively. Additionally, the distributions are similar among Caucasians and African Americans. There was a significant difference between Caucasians and African Americans in the frequency distribution of the two coding SNPs. In comparison with African Americans, Caucasians were more likely to have a G allele of rs1042713 SNP, and less likely to have a C allele of rs1042714 SNP.
Table 3

Allele frequencies of the 5 ADRB2 SNPs (P value compares the frequency difference between Caucasian and African Americans)




African American

P value

(N = 261)

(N = 113)



Allele frequencies (%)


Allele frequencies (%)















































Within each SNP, there was no statistical difference in BSS among each genotype (Figs. 1 and 2). This non statistical difference was consistent within both Caucasians and African Americans. Among African Americans, there was a decreasing trend of the severity of acute respiratory infection with an increasing number of copies of C, C, and A allele of the three promoter SNPs rs1432623, rs11168068, and rs2400707, respectively (Fig. 1). However, analyses with additive models indicated no statistical significance (p > 0.05).
Fig. 1
Fig. 1

BSS distribution across each genotype of 3 promoter SNPs, stratified by race. The scatter plots of the distribution of BSS across genotypes of 3 promoter SNPs (rs1432623, rs11168068, and rs2400707) separately for Caucasian and African American infants. We further overlay box-and-whisker plot of BSS on each scatter plot. P values were obtained from non-parametric Kruskal-Wallis test

Fig. 2
Fig. 2

BSS distribution across each genotype of 2 coding SNPs, stratified by race. The scatter plots of the distribution of BSS across genotypes of 2 coding SNPs (rs1042713 and rs1042714) separately for Caucasian and African American infants. We further overlay box-and-whisker plot of BSS on each scatter plot. P values were obtained from non-parametric Kruskal-Wallis test

Among 25 (32) possible haplotype combinations, only four haplotypes with more than 2 % of frequency were identified (Table 4 and Fig. 3). There were two promoter haplotypes and three coding block haplotypes. There were no statistically significant differences in the promoter and coding block haplotype frequencies between Caucasian and African Americans. However, when all 5 SNPs were combined, the distribution of haplotype frequency was significantly different between Caucasians and African Americans, with genotype CCAAC more common in African Americans and rare in Caucasians (p < 0.001).
Table 4

Haplotype frequencies of the ADRB2 promoter and coding block SNPs (Haplotype genotypes with less than 2 % frequency were not shown in the table)



African Americans

P value

(N = 261)

(N = 113)

Promoter haplotype









Coding block haplotype













Combined haplotype
















Fig. 3
Fig. 3

Linkage disequilibrium (LD) plot in Caucasian (a) and African Americans (b). The plot illustrates the linkage disequilibrium mapping using the HaploView program in Caucasian (a) and African Americans (b) at 5 loci of the B2-adrenergic receptor gene: -2633, -2274, -1343 (in the promoter region), and +46 and +79 (in the coding block)

Promoter haplotype CCA was associated with a decreased BSS in African Americans in a dose dependent manner (p = 0.037 in the univariate analysis) (Fig. 4). Infants without the CCA haplotype had the highest BSS (median 5.5, interquartile range [IQR]: 2.0, 8.0). Infants with one copy of CCA haplotype had a lower bronchiolitis severity score (median 4.0, IQR: 1.0, 7.5). Infants with 2 copies of the CCA haplotype had the comparatively lowest BSS (median 3.0, IQR: 1.0, 4.0). This dose dependent relationship persisted after adjusting for infant age, gender, daycare exposure, secondhand smoke exposure, prior history of breastfeeding, siblings at home, and enrollment season (adjusted odds ratio: 0.59, 95 % confidence interval [CI]: 0.36, 0.98, p = 0.042). This protective effect of CCA haplotype was consistent when we categorized the acute respiratory infection into upper respiratory infection and lower respiratory tract infection. In a similar dose dependent manner, infants with more copies of CCA haplotype were less likely to have lower respiratory tract infection compared with infants with less copies of CCA haplotype (p = 0.05). On the other hand, promoter haplotype TTG was associated with a higher BSS in African Americans (Additional file 1).
Fig. 4
Fig. 4

BSS distribution stratified by copy number of promoter haplotype CCA and separated by race. The scatter plots and the box-and-whisker plots of BSS across 0, 1, and 2 copies of promoter haplotype CCA for both Caucasian and African American infants. P values were obtained from multivariable regression model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of breastfeeding, any siblings at home, and enrollment season

The protective effect of CCA haplotype in African Americans was identified in all combined haplotypes with CCA combination (Figs. 5 and 6). However, due to the sample size, the effect was not statistically significant. In addition, all African American infants with a coding block haplotype GG had CCA combination in their promoter region; therefore, there was a similar additive protective effect of GG in African Americans (Additional file 2). There was no relationship between BSS and the other two coding block haplotypes in African Americans (Additional files 3 and 4). This was also true for the combined haplotypes (Additional files 5 and 6).
Fig. 5
Fig. 5

BSS distribution stratified by copy number of combined haplotype CCAGG and separated by race. The scatter plots and the box-and-whisker plots of BSS across 0, 1, and 2 copies of combined haplotype CCAGG for both Caucasian and African American infants. P values were obtained from multivariable regression model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of breastfeeding, any siblings at home, and enrollment season

Fig. 6
Fig. 6

BSS distribution stratified by copy number of combined haplotype CCAAC in African Americans infants. The scatter plots and the box-and-whisker plots of BSS across 0, 1, and 2 copies of combined haplotype CCAAC for African American infants. P values were obtained from multivariable regression model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of breastfeeding, any siblings at home, and enrollment season

In both Caucasian and African American infants, there were no significant relationships between BSS and coding block haplotypes except for GG haplotype among African Americans (Additional file 2). This was also true for the combined haplotypes. In general, there was no significant relationship between BSS and any haplotypes in Caucasian infants. There was no similar promoter haplotype CCA relationship with BSS in Caucasians as observed in the African Americans (Fig. 4).


In this study we have identified a haplotype in the promoter region of the ADRB2 gene which is associated with a decreased BSS in African American infants. This promoter haplotype of the ADRB2 gene was not associated with the severity of respiratory infections in Caucasian infants. The common coding block polymorphisms, corresponding to amino acid changes at codons 16 and 27, were not associated with a protective effect on severity of respiratory infections in Caucasian or African American infants. Our results agree with the studied conducted by Janssen and colleagues, who found no relationship between the SNP rs1042713 and susceptibility to RSV bronchiolitis in a European population [17].

This observation that the CCA promoter region haplotype is associated with a protective effect on respiratory viral infection severity is similar to our observation in a cohort of adults hospitalized for an asthma exacerbation, where this haplotype was associated with spirometric improvement in response to asthma-specific therapy that included beta-agonists and corticosteroids [34]. In that study, we noted spirometric improvement only in Caucasian patients, although the small number of African American non-responders in that cohort may have limited our ability to detect a similar effect in African Americans [34].

The mechanism by which a haplotype in the promoter region of the ADRB2 gene is associated with a decreased BSS is not known. However, we can speculate that ADRB2 promoter haplotype may alter ADRB2 expression on airway smooth muscle cells and thereby influence basal airway tone. McGraw et al. showed that SNPs in the promoter region of the ADRB2 may regulate gene expression [46]. Moore et al. demonstrated that ADRB2 genetic variants are associated with differences in ADRB2 expression in cultured human airway smooth muscle (HASM) cells, an in vitro system used as a model for changes in the human airway [47] These studies were performed prior to identification of the complex promoter haplotypes, and we are not aware that these haplotypes have been studied in HASM. Small differences in airway tone could thus be important in the setting of acute viral respiratory infections.

Although beyond the scope of the current observational study, we also speculate that ADRB2 genotype might also influence response to bronchiolitis-specific therapy. The primary goal of TCRI was to establish a longitudinal, prospective investigation of infants and their biological mothers on the acute and the long-term health consequences of varying viral respiratory tract infections on early childhood outcomes [37]. Although a BSS was assigned for each infant at acute care visit or hospital admission, we did not study or quantify the effects of different treatments, including beta-agonist therapy. A number of clinical studies have suggested that some infants with bronchiolitis appear to improve with bronchodilator therapy, while on average it is not efficacious [4850]. As ADRB2 is the primary target of bronchodilator therapy, variation in response to beta-agonists might reflect genetic variants in ADRB2.

The diversity of SNPs of the ADRB2 gene was explored by Drysdale et al., using immortalized lymphocytes from 23 Caucasians, 19 African-Americans, 20 Asians, and 15 Hispanic-Latinos [27]. This report from 2000 included the 2 coding block SNPs (+46 and +79) and a number of promoter SNPs extending to 1023 bp upstream of the translation start site. Hawkins et al. examined a 5.3-kb region of the ADRB2 in 429 Caucasians and 240 African-Americans and identified similar minor allele frequencies in the 3 promoter SNPs (-2387, -2274, and -1343) and in the coding block SNPs discussed in this manuscript [28]. Such frequency distributions observed in our study are consistent with the allele frequencies reported in the reference population of the International HapMap Project [51] and Hawkins et al. [28]. Our stratified analyses by race therefore allow us to detect the association between severity of a respiratory illness and haplotype frequency within each racial group, and to minimize the spurious associations due to such population substructure.

We recognize that the significance of our findings is limited by our small sample size and in classifying infants in this study by a severity score rather than by measuring some direct response to bronchodilator therapy. However, BSS correlated with the severity of disease (classified as upper respiratory and lower respiratory illness) well. Our sensitivity analyses with the severity of disease (upper versus lower respiratory illness) showed consistent results indicated that BSS is a valid surrogate of disease severity. Lastly, although a p value of 0.042 is at the threshold of statistical significance, this p value reflects sample size of 113 African Americans in our study. Whether the association between BSS and CCA haplotype in African Americans is powerful or not depends upon not only p value, but also upon the effect size such as odds ratio and the clinical significance of the findings. As a difference of 0.5 in BSS is considered as clinically significant, a 65 % reduced odds of developing a more severe disease (higher BSS) comparing 2 copies of CCA with 0 copy of CCA might also be clinically significant and meaningful.

We hope that this hypothesis-generating study will encourage the incorporation of pharmacokinetic data in future studies of bronchiolitis. Although validation studies in other populations are needed, this study underscores that the development of personalized approaches to the treatment of bronchiolitis may benefit from the analysis of specific genetic variants.


In summary, we have observed that promoter region haplotype of ADRB2 CCA is associated with a protective effect on respiratory illness severity in African American infants. In this era of personalized medicine, ADRB2 genotype may be predictive of the severity of respiratory viral infection and potential response to therapy for the most common acute infant illness and one for which we currently have no therapy. Next steps would be to validate these findings, as well as evaluate available clinical trial data for which DNA might be available.



We would like to thank the families, pediatricians and their staff, who participated in The Tennessee Children’s Respiratory Initiative. This work was supported by Thrasher Research Fund Clinical Research Grant (to TVH), NIH mid-career investigator award K24 AI 077930 (to TVH), UL1 RR024975 (Vanderbilt CTSA), NIH AI U19-AI-095277 (to TVH), NIH K12 HD 043483 (to PW), and NIH K01 AI070808 mentored clinical scientist award (to KNC). TVH is also supported by NIH U01 HL 072471 [which supports the Tennessee Asthma Bronchiolitis Study (TABS) cohort], R01 AI 05884, and NIH K12 ES 015855).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Center for Asthma & Environmental Health Sciences Research, Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Suite 6100 Medical Center East, Nashville, TN 37232, USA
Department of Pediatrics, Vanderbilt University School of Medicine, 313 Oxford House, Nashville, TN 37232, USA
Department of Genetics and Metabolism, Division of Genetics and Metabolism, Children’s National Health System, 111 Michigan Avenue, NW, Washington, DC 20010, USA
Department of Biostatistics, Vanderbilt University School of Medicine, 2525 West end Ave, Suite 1100, Nashville, TN 37203, USA
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
Division of Pediatric Allergy, Immunology and Pulmonary, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 Children’s Way, 11215 Doctor’s Office Tower, Nashville, TN 37232, USA


  1. Mizgerd JP. Lung infection--a public health priority. PLoS Med. 2006;3(2):e76. doi:10.1371/journal.pmed.0030076.PubMedPubMed CentralGoogle Scholar
  2. Wright AL, Taussig LM, Ray CG, Harrison HR, Holberg CJ. The Tucson Children’s Respiratory Study. II. Lower respiratory tract illness in the first year of life. Am J Epidemiol. 1989;129(6):1232–46.PubMedGoogle Scholar
  3. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6.PubMedGoogle Scholar
  4. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-93. doi:10.1542/peds.2006-2223.
  5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440–6.PubMedGoogle Scholar
  6. Yorita KL, Holman RC, Sejvar JJ, Steiner CA, Schonberger LB. Infectious disease hospitalizations among infants in the United States. Pediatrics. 2008;121(2):244–52. doi:10.1542/peds.2007-1392.PubMedGoogle Scholar
  7. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161(5):1501–7. doi:10.1164/ajrccm.161.5.9906076.PubMedGoogle Scholar
  8. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137–41. doi:10.1164/rccm.200406-730OC.PubMedGoogle Scholar
  9. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–52. doi:10.1136/thx.2009.121582.PubMedGoogle Scholar
  10. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16(5):386–92. doi:10.1111/j.1399-3038.2005.00298.x.PubMedGoogle Scholar
  11. Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child. 1997;76(4):315–9.PubMedPubMed CentralGoogle Scholar
  12. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003;22(2 Suppl):S76–82. doi:10.1097/01.inf.0000053889.39392.a7.PubMedGoogle Scholar
  13. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med. 2015;191(1):34–44. doi:10.1164/rccm.201405-0901PP.PubMedPubMed CentralGoogle Scholar
  14. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. Plos One. 2014;9(2):e89186. doi:10.1371/journal.pone.0089186.PubMedPubMed CentralGoogle Scholar
  15. Wainwright C. Acute viral bronchiolitis in children- a very common condition with few therapeutic options. Paediatr Respir Rev. 2010;11(1):39-45; quiz doi:10.1016/j.prrv.2009.10.001.
  16. Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics. 2008;122(1):58–64. doi:10.1542/peds.2007-2087.PubMedPubMed CentralGoogle Scholar
  17. Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, Doornbos G, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis. 2007;196(6):826–34. doi:10.1086/520886.PubMedGoogle Scholar
  18. Daley D, Park JE, He JQ, Yan J, Akhabir L, Stefanowicz D, et al. Associations and interactions of genetic polymorphisms in innate immunity genes with early viral infections and susceptibility to asthma and asthma-related phenotypes. J Allergy Clin Immunol. 2012;130(6):1284–93. doi:10.1016/j.jaci.2012.07.051.PubMedGoogle Scholar
  19. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis. 2004;189(11):2057–63. doi:10.1086/420830.PubMedGoogle Scholar
  20. Lofgren J, Marttila R, Renko M, Ramet M, Hallman M. Toll-like receptor 4 Asp299Gly polymorphism in respiratory syncytial virus epidemics. Pediatr Pulmonol. 2010;45(7):687–92. doi:10.1002/ppul.21248.PubMedGoogle Scholar
  21. Amanatidou V, Sourvinos G, Apostolakis S, Neonaki P, Tsilimigaki A, Krambovitis E, et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J. 2008;27(1):38–42. doi:10.1097/INF.0b013e31814d4e42.PubMedGoogle Scholar
  22. Mulet JF, Rodriguez de Torres BO. [Viral induced bronchiolitis and genetics]. An Pediatr (Barc). 2010;73(4):159-61. doi:10.1016/j.anpedi.2010.08.001.
  23. Siezen CL, Bont L, Hodemaekers HM, Ermers MJ, Doornbos G, Van’t Slot R, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J. 2009;28(4):333–5. doi:10.1097/INF.0b013e31818e2aa9.PubMedGoogle Scholar
  24. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995;13(1):25–33. doi:10.1165/ajrcmb.13.1.7598936.PubMedGoogle Scholar
  25. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33(32):9414–9.PubMedGoogle Scholar
  26. Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics. 2008;9(3):349–58. doi:10.2217/14622416.9.3.349.PubMedGoogle Scholar
  27. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97(19):10483–8.PubMedPubMed CentralGoogle Scholar
  28. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med. 2006;174(10):1101–9. doi:10.1164/rccm.200509-1405OC.PubMedPubMed CentralGoogle Scholar
  29. Panebra A, Wang WC, Malone MM, Pitter DR, Weiss ST, Hawkins GA, et al. Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. Plos One. 2010;5(7):e11819. doi:10.1371/journal.pone.0011819.PubMedPubMed CentralGoogle Scholar
  30. Singh AM, Moore PE, Gern JE, Lemanske Jr RF, Hartert TV. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. Am J Respir Crit Care Med. 2007;175(2):108–19. doi:10.1164/rccm.200603-435PP.PubMedGoogle Scholar
  31. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med. 2010;181(7):676–87. doi:10.1164/200809-1511OC.PubMedGoogle Scholar
  32. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118(4):809–16. doi:10.1016/j.jaci.2006.06.036.PubMedGoogle Scholar
  33. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374(9703):1754–64. doi:10.1016/S0140-6736(09)61492-6.PubMedPubMed CentralGoogle Scholar
  34. Moore PE, Williams SM, Gebretsadik T, Jiang L, Minton PL, Shintani A, et al. beta(2)-adrenergic receptor promoter haplotype influences spirometric response during an acute asthma exacerbation. Clin Transl Sci. 2008;1(2):155–61. doi:10.1111/j.1752-8062.2008.00036.x.PubMedPubMed CentralGoogle Scholar
  35. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ. 2011;342:d1714. doi:10.1136/bmj.d1714.PubMedPubMed CentralGoogle Scholar
  36. Tse SM, Gold DR, Sordillo JE, Hoffman EB, Gillman MW, Rifas-Shiman SL, et al. Diagnostic accuracy of the bronchodilator response in children. J Allergy Clin Immunol. 2013;132(3):554–9. doi:10.1016/j.jaci.2013.03.031. e5.PubMedPubMed CentralGoogle Scholar
  37. Hartert TV, Carroll K, Gebretsadik T, Woodward K, Minton P. The Tennessee Children’s Respiratory Initiative: Objectives, design and recruitment results of a prospective cohort study investigating infant viral respiratory illness and the development of asthma and allergic diseases. Respirology. 2010;15(4):691–9. doi:10.1111/j.1440-1843.2010.01743.x.PubMedPubMed CentralGoogle Scholar
  38. Carroll KN, Gebretsadik T, Minton P, Woodward K, Liu Z, Miller EK, et al. Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. J Allergy Clin Immunol. 2012;129(5):1236–42. doi:10.1016/j.jaci.2012.01.045.PubMedPubMed CentralGoogle Scholar
  39. Carroll KN, Gebretsadik T, Larkin EK, Dupont WD, Liu Z, Van Driest S et al. Relationship of maternal vitamin D level with maternal and infant respiratory disease. American journal of obstetrics and gynecology. 2011;205(3):215 e1-7. doi:10.1016/j.ajog.2011.04.002.
  40. McCallum GB, Morris PS, Wilson CC, Versteegh LA, Ward LM, Chatfield MD, et al. Severity scoring systems: are they internally valid, reliable and predictive of oxygen use in children with acute bronchiolitis? Pediatr Pulmonol. 2013;48(8):797–803. doi:10.1002/ppul.22627.PubMedGoogle Scholar
  41. Hutchison KE, Stallings M, McGeary J, Bryan A. Population stratification in the candidate gene study: fatal threat or red herring? Psychol Bull. 2004;130(1):66–79. doi:10.1037/0033-2909.130.1.66.PubMedGoogle Scholar
  42. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005;76(5):887–93. doi:10.1086/429864.PubMedPubMed CentralGoogle Scholar
  43. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296(5576):2225–9. doi:10.1126/science.1069424.PubMedGoogle Scholar
  44. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978–89. doi:10.1086/319501.PubMedPubMed CentralGoogle Scholar
  45. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73(5):1162–9. doi:10.1086/379378.PubMedPubMed CentralGoogle Scholar
  46. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102(11):1927–32. doi:10.1172/JCI4862.PubMedPubMed CentralGoogle Scholar
  47. Moore PE, Laporte JD, Abraham JH, Schwartzman IN, Yandava CN, Silverman ES, et al. Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med. 2000;162(6):2117–24. doi:10.1164/ajrccm.162.6.9909046.PubMedGoogle Scholar
  48. Goebel J, Estrada B, Quinonez J, Nagji N, Sanford D, Boerth RC. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clin Pediatr. 2000;39(4):213–20.Google Scholar
  49. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;6:CD001266. doi:10.1002/14651858.CD001266.pub4.PubMedGoogle Scholar
  50. Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics. 1983;71(1):13–8.PubMedGoogle Scholar
  51. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res. 2005;15(11):1592–3. doi:10.1101/gr.4413105.PubMedPubMed CentralGoogle Scholar


© Wu et al. 2015